Cargando…
Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?
Interfering with mitosis for cancer treatment is an old concept that has proven highly successful in the clinics. Microtubule poisons are used to treat patients with different types of blood or solid cancer since more than 20 years, but how these drugs achieve clinical response is still unclear. Arr...
Autores principales: | Haschka, Manuel, Karbon, Gerlinde, Fava, Luca L, Villunger, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836099/ https://www.ncbi.nlm.nih.gov/pubmed/29459486 http://dx.doi.org/10.15252/embr.201745440 |
Ejemplares similares
-
The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents
por: Karbon, Gerlinde, et al.
Publicado: (2021) -
MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
por: Haschka, Manuel D., et al.
Publicado: (2020) -
The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
por: Haschka, Manuel D., et al.
Publicado: (2015) -
The BH3-only protein Bad is dispensable for TNF-mediated cell death
por: Ottina, E, et al.
Publicado: (2015) -
The p53 binding protein PDCD5 is not rate-limiting in DNA damage induced cell death
por: Bock, Florian J., et al.
Publicado: (2015)